Market Overview

UPDATE: Morgan Stanley Reiterates On St. Jude Medical On Mixed Factors

Related STJ
St. Jude Medical Receives CE Mark for New Infinity Deep Brain Stimulation System and Directional DBS Lead
St. Jude Confirms 5-Year Data from FAME Trial Further Confirms Sustained, Long Term Benefit of FFR-Guided PCI
The Worst Of October's 742 All CCC Companies (Seeking Alpha)

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on St. Jude Medical (NYSE: STJ), but removed the $75.00 price target.

In the report, Morgan Stanley noted, “We remain comfortable that St. Jude's top line is poised for acceleration given underlying business strength, CRT-D momentum and CardioMEMs. However, Nanostim's early European failures and MDT's more positive comparative experience did raise concerns at HRS.”

St. Jude Medical closed on Thursday at $63.22.

Latest Ratings for STJ

Aug 2015Credit SuisseAssumesOutperform
Jul 2015Deutsche BankDowngradesBuyHold
Jul 2015BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for STJ
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (STJ)

View Comments and Join the Discussion!

Get Benzinga's Newsletters